Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18932596 | 0.77 | SLC9A1 (0.43) | SLC9A1RIPK1S1PR5S1PR4FFAR4 | |
| SCHEMBL18889292 | 0.76 | RIPK1 (0.60) | SLC9A1RIPK1S1PR5S1PR4FFAR4 | |
| SCHEMBL9209273 | 0.72 | HDAC3 (0.47) | SLC9A1 | |
| Hydrochloric Acid SCHEMBL18889264 | 0.72 | RIPK1 (0.53) | SLC9A1RIPK1FFAR4F9 | |
| SCHEMBL18889267 | 0.72 | SLC9A1 (0.68) | SLC9A1RIPK1F9 | |
| SCHEMBL28115367 | 0.70 | PLAU (0.47) | SLC9A1 | |
| SCHEMBL829128 | 0.68 | SLC9A1 (0.62) | SLC9A1RIPK1 | |
| SCHEMBL28280395 | 0.66 | HSD17B1 (0.44) | — | |
| SCHEMBL825969 | 0.66 | SLC9A1 (1.00) | SLC9A1 | |
| SCHEMBL3470157 | 0.65 | GFER (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3176163-B1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | IAC IN NAT UNIV CHUNGNAM (KR) | 2019-04-17 | — | — | EP | disclosed |
| EP-3176163-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) | 2017-06-07 | — | — | EP | disclosed |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | MOTHER'S PHARMACEUTICAL CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | RIPK1, RIPK2, RIPK3 | SLC9A1 2031/4885RIPK1 1/4885S1PR5 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.